

Supplementary Table 3. Comparison of baseline characteristics between matched cohorts: TACE vs. IO

Characteristic	Treatment		P-value
	TACE (n=19)	IO (n=19)	
Age (years)	52.6±12.5	57.9±13.0	0.212
Male	15 (78.9)	15 (78.9)	1.000
Etiology			0.656
Viral	17 (89.5)	15 (78.9)	
NBNC	2 (10.5)	4 (21.1)	
ECOG performance status			1.000
0	16 (84.2)	17 (89.5)	
≥1	3 (15.8)	2 (10.5)	
ALBI grade			1.000
1	13 (68.4)	14 (73.7)	
≥2	6 (31.6)	5 (26.3)	
Size (cm)			0.656
<5	2 (10.5)	4 (21.1)	
≥5	17 (89.5)	15 (78.9)	
Number			1.000
<3	6 (31.6)	5 (26.3)	
≥3	13 (68.4)	14 (73.7)	
Log (AFP)	7.4±3.8	5.5±3.4	0.115
Log (PIVKA-II)	8.1±2.6	7.3±3.0	0.380
PV invasion			0.547
None	12 (63.2)	10 (52.6)	
Segmental/lobar	5 (26.3)	8 (42.1)	
Main/contralateral	2 (10.5)	1 (5.3)	
Extrahepatic metastasis type			0.352
Nodal metastasis	6 (31.6)	8 (42.1)	
Distant metastasis	12 (63.2)	8 (42.1)	
Nodal plus distant metastasis	1 (5.3)	3 (15.8)	

Values are presented as mean±standard deviation or number (%).

TACE, transarterial chemoembolization; IO, immunotherapy; NBNC, non-B and non-C; ECOG, Eastern Cooperative Oncology Group; ALBI, albumin-bilirubin; AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by vitamin K absence-II; PV, portal vein.